Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1.

Wilfret DA, Walker J, Adkison KK, Jones LA, Lou Y, Gan J, Castellino S, Moseley CL, Horton J, de Serres M, Culp A, Goljer I, Spreen W.

Antimicrob Agents Chemother. 2013 Oct;57(10):5037-44. doi: 10.1128/AAC.00910-13. Epub 2013 Jul 29.

PMID:
23896477
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.

de Bruijne J, van Vliet A, Weegink CJ, Mazur W, Wiercinska-Drapało A, Simon K, Cholewińska-Szymańska G, Kapocsi J, Várkonyi I, Zhou XJ, Temam MF, Molles J, Chen J, Pietropaolo K, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Reesink H.

Antivir Ther. 2012;17(4):633-42. doi: 10.3851/IMP2078. Epub 2012 Mar 16.

PMID:
22427481
[PubMed - indexed for MEDLINE]
3.

A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.

Gardner S, Cutrell A, Elko-Simms C, Adkison K, Hamatake R, Walker J, Rodriguez-Torres M, Hong Z.

Liver Int. 2014 Jul;34(6):e89-95. doi: 10.1111/liv.12334. Epub 2013 Oct 16.

PMID:
24107072
[PubMed - in process]
4.

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM.

J Hepatol. 2012 Jul;57(1):24-31. doi: 10.1016/j.jhep.2011.12.029. Epub 2012 Feb 5.

PMID:
22314425
[PubMed - indexed for MEDLINE]
5.

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.

Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van 't Klooster G, Lenz O, Aharchi F, Mariën K, Van Remoortere P, de Kock H, Broeckaert F, Meyvisch P, Van Beirendonck E, Simmen K, Verloes R.

Gastroenterology. 2010 Mar;138(3):913-21. doi: 10.1053/j.gastro.2009.10.033. Epub 2009 Oct 21.

PMID:
19852962
[PubMed - indexed for MEDLINE]
6.

Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.

Hotho DM, de Bruijne J, O'Farrell AM, Boyea T, Li J, Bracken M, Li X, Campbell D, Guler HP, Weegink CJ, Schinkel J, Molenkamp R, van de Wetering de Rooij J, van Vliet A, Janssen HL, de Knegt RJ, Reesink HW.

Antivir Ther. 2012;17(2):365-75. doi: 10.3851/IMP1989. Epub 2011 Nov 30.

PMID:
22293533
[PubMed - indexed for MEDLINE]
7.

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.

Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF.

Lancet. 2010 Oct 30;376(9751):1467-75. doi: 10.1016/S0140-6736(10)61384-0. Epub 2010 Oct 14.

PMID:
20951424
[PubMed - indexed for MEDLINE]
8.

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.

Wagner F, Thompson R, Kantaridis C, Simpson P, Troke PJ, Jagannatha S, Neelakantan S, Purohit VS, Hammond JL.

Hepatology. 2011 Jul;54(1):50-9. doi: 10.1002/hep.24342.

PMID:
21488067
[PubMed - indexed for MEDLINE]
9.

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.

Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, Goldwater R, DeMicco MP, Rodriguez-Torres M, Vutikullird A, Fuentes E, Lawitz E, Lopez-Talavera JC, Grasela DM.

Hepatology. 2011 Dec;54(6):1956-65. doi: 10.1002/hep.24609.

PMID:
21837752
[PubMed - indexed for MEDLINE]
10.

Echocardiogram study to evaluate the effect of the novel hepatitis C virus NS5A inhibitor GSK2336805 on cardiac contractility in healthy subjects.

Wilfret DA, Adkison KK, Jones LA, Lou Y, Gan J, Spreen W.

Antimicrob Agents Chemother. 2013 Oct;57(10):5141-3. doi: 10.1128/AAC.00668-13. Epub 2013 Jul 15.

PMID:
23856771
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.

Gane EJ, Rouzier R, Stedman C, Wiercinska-Drapalo A, Horban A, Chang L, Zhang Y, Sampeur P, Nájera I, Smith P, Shulman NS, Tran JQ.

J Hepatol. 2011 Nov;55(5):972-9. doi: 10.1016/j.jhep.2011.01.046. Epub 2011 Feb 24.

PMID:
21354234
[PubMed - indexed for MEDLINE]
12.

Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.

Roberts SK, Cooksley G, Dore GJ, Robson R, Shaw D, Berns H, Hill G, Klumpp K, Najera I, Washington C.

Hepatology. 2008 Aug;48(2):398-406. doi: 10.1002/hep.22321.

PMID:
18553458
[PubMed - indexed for MEDLINE]
13.

Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.

Lawitz E, Rodriguez-Torres M, Denning JM, Albanis E, Cornpropst M, Berrey MM, Symonds WT.

Antimicrob Agents Chemother. 2013 Mar;57(3):1209-17. doi: 10.1128/AAC.01263-12. Epub 2012 Dec 21.

PMID:
23263000
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.

Denning J, Cornpropst M, Flach SD, Berrey MM, Symonds WT.

Antimicrob Agents Chemother. 2013 Mar;57(3):1201-8. doi: 10.1128/AAC.01262-12. Epub 2012 Dec 21.

PMID:
23262999
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.

Larrey D, Lohse AW, Trepo C, Bronowicki JP, Arastéh K, Bourlière M, Calleja JL, Stern JO, Nehmiz G, Abdallah N, Berger KL, Marquis M, Steffgen J, Kukolj G; BI 207127 Study Group.

Antimicrob Agents Chemother. 2013 Oct;57(10):4727-35. doi: 10.1128/AAC.00565-13. Epub 2013 Jul 15.

PMID:
23856779
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.

Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Sheridan P, Persson A, Huang SP, Hernandez D, Sheaffer AK, Scola P, Marbury T, Lawitz E, Goldwater R, Rodriguez-Torres M, Demicco M, Wright D, Charlton M, Kraft WK, Lopez-Talavera JC, Grasela DM.

Antimicrob Agents Chemother. 2012 Apr;56(4):1838-44. doi: 10.1128/AAC.05854-11. Epub 2012 Jan 30.

PMID:
22290978
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.

Vince B, Hill JM, Lawitz EJ, O'Riordan W, Webster LR, Gruener DM, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Zhou XJ.

J Hepatol. 2014 May;60(5):920-7. doi: 10.1016/j.jhep.2014.01.003. Epub 2014 Jan 14.

PMID:
24434503
[PubMed - in process]
Free Article
18.

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.

Rev Invest Clin. 2003 Mar-Apr;55(2):138-42.

PMID:
12827916
[PubMed - indexed for MEDLINE]
19.

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.

Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, Smith P, Bradford W, Porter S, Blatt L, Seiwert SD, Zeuzem S.

J Hepatol. 2011 Jun;54(6):1130-6. doi: 10.1016/j.jhep.2010.11.001. Epub 2011 Feb 24.

PMID:
21145848
[PubMed - indexed for MEDLINE]
20.

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.

Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E, Bourlière M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF.

Gastroenterology. 2014 Feb;146(2):420-9. doi: 10.1053/j.gastro.2013.10.057. Epub 2013 Oct 30.

PMID:
24184132
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk